Skip to main content
. 2021 Feb 12;11:620374. doi: 10.3389/fimmu.2020.620374

Figure 2.

Figure 2

Key parameters to optimize the success of DC-based immunotherapy. CTLA-4, cytotoxic T lymphocyte-associated antigen 4; DC, dendritic cell; MTD, maximum tolerated dose; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.